ACRUX LIMITED — Board/Management Information 2016

Dec 7, 2016

ACRUX (ACR) - ASX ANNOUNCEMENT 8 DECEMBER 2016

ACRUX ANNOUNCES DIRECTOR RESIGNATION

==> picture [482 x 10] intentionally omitted <==

Acrux (ASX: ACR) today announced the resignation of Mr Bruce Parncutt, NonExecutive Director.

Bruce joined the Acrux Board on 30 April 2012.

The Board would like to thank Bruce for the significant contribution he has made to the development of the Company’s growth strategy and extends both its appreciation for his role within the Company and best wishes for success in his future endeavors.

For further information, contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising specialty and generic topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of pharmaceutical products in the US and Europe using the Patchless Patch™, a fast-drying and invisible topical application technology. Marketed products include Axiron[®] , Evamist[®] and Lenzetto[®] . More recently, in addition to specialty products, Acrux has identified and initiated development of a range of generic products. Acrux is leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring more products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au

==> picture [540 x 82] intentionally omitted <==